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Abstract
Background: Little is known about the patterns of brain atrophy in prodromal dementia with Lewy bodies (pro-DLB).
Methods: In this study, we used SPM8 with diffeomorphic anatomical registration through exponentiated lie algebra
to measure grey matter (GM) volume and investigate patterns of GM atrophy in pro-DLB (n = 28) and prodromal
Alzheimer’s disease (pro-AD) (n = 27) and compared and contrasted them with those in elderly control subjects (n = 33)
(P≤ 0.05 corrected for family-wise error).
Results: Patients with pro-DLB showed diminished GM volumes of bilateral insulae and right anterior cingulate cortex
compared with control subjects. Comparison of GM volume between patients with pro-AD and control subjects
showed a more extensive pattern, with volume reductions in temporal (hippocampi and superior and middle gyri),
parietal and frontal structures in the former. Direct comparison of prodromal groups suggested that more atrophy was
evident in the parietal lobes of patients with pro-AD than patients with pro-DLB. In patients with pro-DLB, we found
that visual hallucinations were associated with relative atrophy of the left cuneus.
Conclusions: Atrophy in pro-DLB involves the insulae and anterior cingulate cortex, regions rich in von Economo
neurons, which we speculate may contribute to the early clinical phenotype of pro-DLB.
Keywords: Prodromal dementia with Lewy bodies, Dementia with Lewy bodies, Alzheimer’s disease, Alzheimer’s
dementia, Prodromal Alzheimer’s disease, Lewy body disease, Mild cognitive impairment, MRI, Insula
Background
Dementia with Lewy bodies (DLB) is the second most com-
mon form of dementia after Alzheimer’s disease (AD), ac-
counting for 15–20 % of neuropathologically defined cases
[1]. Diagnostic classification of DLB is based on revised
consensus criteria, with core diagnostic features of DLB be-
ing (1) recurrent visual hallucinations, (2) cognitive fluctua-
tions and (3) spontaneous motor features of parkinsonism
[1]. The presence of two or three of these core signs is suffi-
cient for a diagnosis of probable DLB [1] at the stage of
dementia, and this overlaps with the recent nomenclature
update in the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V), where probable DLB is
now comes under the heading of ‘major neurocognitive
disorder with Lewy bodies’ [2]. In addition, DSM-V has the
diagnostic classification of mild neurocognitive disorder
with Lewy bodies. Thus, there is formal recognition that
there is a pre-dementia state of this disease [2], similar to
AD, where there is underlying neurodegenerative disease
but function has not yet been compromised. This state has
also been referred to as prodromal DLB (pro-DLB), a term
which we use in this paper.
Distinguishing DLB from AD at the dementia stage is
difficult because of overlapping clinical and neuropatho-
logical features between the two conditions, as well as
because specific symptoms of DLB, such as hallucina-
tions or fluctuations, are not spontaneously described by
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the patient and the caregiver. At early or prodromal
stages, the challenges are even greater, given the subtlety
of symptoms present. Whilst cognitive patterns in pro-
DLB have been described as different from prodromal
AD (pro-AD) [3, 4], with patients with DLB at this early
stage having more visuospatial and fluency deficits than
those with AD, and patients with AD having more am-
nesic impairments than those with DLB [4, 5], the
neuropsychological pattern of pro-DLB appears to be
more heterogeneous than that in pro-AD [5]. However,
verbal memory [6] and visual memory impairments are
frequent at the early stage of DLB, as in AD [7], and that
is the reason why the differentiation of AD and DLB is
difficult at the individual level. The behaviour modifica-
tions are also common in the two diseases: anxiety and
depressive symptoms are frequent and do not permit
differentiate of the two diseases [8, 9].
However, accurate differentiation of DLB and AD, re-
gardless of the stage of the disease, is important clinic-
ally, given different management trajectories for each
disease (e.g., avoidance of neuroleptics in DLB, but likely
better response to cholinesterase inhibitors [10]) as well
as prognosis [11]. Furthermore, accurate early subtype
diagnosis of the underlying neurodegenerative cause is
becoming increasingly important for ensuring that fu-
ture disease-modifying treatments can be targeted in in-
dividuals before substantive neurodegenerative deficits
have occurred. Similarly, identification and validation of
early biomarkers of pro-DLB will further assist in the de-
velopment of pro-DLB criteria [12]. Specifically, for pur-
poses of our analyses, and in alignment with our
previous work [13], we consider individuals with pro-
DLB to be those patients who meet the revised diagnos-
tic criteria for DLB, but, instead of dementia [1], fit the
criteria for mild cognitive impairment (MCI) [14].
Structural neuroimaging represents one potential bio-
marker area, and a well-established method is the use of
voxel-based morphometry (VBM) to study atrophic
change in dementia. Comparison of VBM and a manual
method for hippocampal volumetry to detect temporal
lobe atrophy in AD showed that VBM with or without
diffeomorphic anatomical registration through exponen-
tiated lie algebra (DARTEL) registration is equivalent or
more accurate [15, 16]. But VBM-DARTEL seems to be
more accurate at detecting hippocampal atrophy in sub-
tle cases, such as in depression [17]. This image-
processing technique is also useful in many others
neurological or psychiatric diseases including depression,
schizophrenia, temporal lobe epilepsy, [18] but also MCI
Parkinson’s disease [19].
Previous VBM studies in DLB at the stage of dementia
have demonstrated diminished volume in the insulae bi-
laterally and in the lateral temporal lobes, frontal lobe
and precuneus [20], and others have reported grey
matter (GM) volumetric reductions in the mid-brain, the
substantia innominata, the hypothalamus and the right
insula [21], and these findings are confirmed by a voxel-
wise meta-analysis on cortical atrophy of patients with
DLB at the stage of dementia whose authors found bilat-
eral insulae and basal ganglia atrophy [22]. Furthermore,
this resonates with recent findings from our group. We
demonstrated that the cortical thickness of patients with
pro-DLB is diminished in the right anterior part of the
insula [13]. This novel finding is significant, since pa-
tients at the early stage of the disease frequently have
neurovegetative symptoms such as constipation, ortho-
static dizziness or increased saliva, symptoms domains
[23] which have been linked to insula. At the early stage,
patients also frequently have cognitive fluctuations and
hallucinations, and insular dysfunction has also been im-
plicated in these symptoms [24, 25]. Contrarily, given
that parkinsonism is rarely obvious at the beginning of
the DLB, one might expect the putamen, pallidum and
substantia nigra regions would be less structurally af-
fected earlier in the disease [26]. However, data on sub-
cortical structure were previously unexplored, since
cortical in thickness studies researchers analysed only
the cortex and not the hippocampi or basal ganglia [13].
Therefore, the primary aim of this study was to inves-
tigate cortical and subcortical grey matter (GM) atrophy
patterns in patients with pro-DLB, and we report mag-
netic resonance imaging (MRI) patterns of GM atrophy
in subjects with DLB at the stage of MCI (pro-DLB) and
AD at the stage of MCI (pro-AD) compared with healthy
elderly control subjects (HC). We hypothesised that, in
pro-AD, the pattern of GM atrophy would involve pre-
dominantly the temporal lobe and parietal association
cortices in keeping with the significant body of evidence
supporting volumetric losses in these areas in pro-AD
[27]. In contrast, we expected that the pattern of GM at-
rophy in pro-DLB would be less marked and more spe-
cific to structures such as the insulae.
Methods
Subjects, assessments and diagnosis
One hundred individuals suspected of having DLB or
AD and HC over the age of 50 years were recruited (see
Fig. 1 flowchart) from two European centres. Thirty-six
were recruited from a community-dwelling population
of patients referred to local old age psychiatry, geriatric
medicine or neurology services in Newcastle upon Tyne
(NCL); 64 were recruited from the tertiary memory
clinic of Strasbourg (SXB), including neurology and geri-
atric medicine services. HC were recruited from estab-
lished case registers. These subjects were previously
included in a study of cortical thickness [13]. Subjects
underwent detailed clinical and neuropsychological eval-
uations. Common elements between centres included
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the assessment of motor parkinsonism with the Unified
Parkinson’s Disease Rating Scale Part III (UPDRS-III)
[28], the Clinician Assessment of Fluctuation (CAF)
[29], the Mini Mental State Examination (MMSE), the
Clinical Dementia Rating scale (CDR) and the Trail
Making Task A and B (TMTA and TMTB, respectively).
For TMTA and TMTB, normative data from Tombaugh
were used [30]. The neuropsychological evaluation of
SXB included the Free and Cued Selective Reminding
Tests for verbal memory, 48-item delayed matching to
sample for visual recognition memory, forward and
backward digit span, Wechsler Adult Intelligence Scale
code for attention and speed processing, Frontal Assess-
ment Battery and phonemic fluency for executive func-
tion, semantic fluency, oral denomination 80 items for
language, the Rey-Osterrieth Complex Figure Test, and
Mahieux praxis evaluation. The neuropsychological
evaluation done at NCL was a comprehensive neuro-
psychological battery: the Cambridge Cognitive Examin-
ation as well as the F-A-S test and semantic fluency. For
the purposes of this paper, we report only those scales
which were common to both centres (e.g., MMSE,
TMTA and TMTB).
Patients in the SXB group also underwent cerebrospinal
fluid (CSF) analysis, including measurement of tau,
phospho-tau, and amyloid-β1–42 (Aβ1–42; cut-off<500 ng/L)
(INNOTEST® enzyme-linked immunosorbent assay;
Fujirebio Europe, Gent, Belgium). Visual assessment of
medial temporal atrophy on brain MRI scans was per-
formed using the standardised Scheltens scale (five cat-
egories, range 0–4), with 0 corresponding to no
atrophy [31]. The diagnosis of neurocognitive disorder
for each patient was made using the Dubois et al. cri-
teria for pro-AD (n = 27) [32]. Patients with pro-DLB
(n = 28) were defined as patients with MCI (Petersen
criteria) [33] and a CDR of 0 or 0.5, and also by the
McKeith et al. criteria (meeting probable DLB criteria
except presence of dementia) [1], which is consistent
with recent suggestions regarding pro-DLB criteria
[12]. Similarly, 33 aged healthy and cognitively intact
(no MCI) subjects were recruited from among relatives
and friends of subjects with neurocognitive disorders
and individuals who volunteered via advertisements in
local community newsletters in NCL and SXB areas.
Exclusion criteria for participation in the study in-
cluded contraindications for MRI, history of alcohol/
substance misuse, evidence suggesting alternative
neurological or psychiatric explanations for symptoms/
cognitive impairment, focal brain lesions seen on brain
imaging or the presence of other severe or unstable
medical illness. All patients had formal assessment of
their diagnosis done by independent expert clinicians
(JPT and FB for NCL; and FB, BC and NP for SXB),
and HC underwent clinical and cognitive assessments
similar to those of patients to exclude any who may
have had an occult MCI or dementia. Patients with
concomitant AD and DLB (i.e., those meeting both
McKeith et al. [for probable DLB] and Dubois et al.
criteria) were excluded (see Fig. 1).
MRI data acquisition
Subjects in the NCL and SXB groups underwent T1-
weighted MRI on a 3-T MRI system within 2 months of
the study assessment. NCL investigators used an 8-
channel head coil (Intera Achieva scanner; Philips
Medical Systems, Eindhoven, The Netherlands), and
SXB researchers used a 32-channel head coil (Siemens
Magnetom Verio syngo MR B17; Siemens Medical
Solutions, Malvern, PA, USA). The sequence obtained
was a standard T1-weighted volumetric sequence cov-
ering the whole brain (3D magnetization-prepared
rapid gradient echo, sagittal acquisition, 1-mm
isotropic resolution). Three-dimensional (3D) T1-
weighted images of the NCL group had a matrix size of
240 (anterior-posterior) × 240 (superior-inferior) × 180
Fig. 1 Flowchart of the present study on grey matter atrophy in
prodromal stages of dementia with Lewy bodies and Alzheimer’s
disease. Prodromal DLB is defined as patients with the McKeith et al.
criteria of DLB with cognitive impairment but without dementia.
Psychiatric pathologies included two patients with depression, one
with bipolar disorder and one with histrionic personality disorder. In
addition, among patients with MCI, one had cognitive impairment
due to severe sleep apnoea, one had vitamin B12 encephalopathy
and one had mitochondriopathy. AD Alzheimer’s disease, DLB
dementia with Lewy bodies, MCI mild cognitive impairment
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(right-left), a repetition time (TR) of 9.6 milliseconds,
an echo time (TE) of 4.6 milliseconds and a flip angle
of 8 degrees. 3D T1-weighted images of the SXB group
had a matrix size of 192 (anterior-posterior) × 192
(superior-inferior) × 176 (right-left), a TR of 1900 milli-
seconds, a TE of 2.53 milliseconds and a flip angle of 9
degrees. The acquired volume was angulated such that the
axial slice orientation was standardised to align with the
anterior commissure-posterior commissure line.
VBM-DARTEL
Analysis was conducted using the SPM8 software package
(http://www.fil.ion.ucl.ac.uk/spm) running on MATLAB
7.9 (MathWorks, Natick, MA, USA). First, MRI scans
were segmented into GM, white matter (WM) and CSF
using SPM8’s standard unified segmentation module [34].
Second, using the DARTEL technique [35], a GM popula-
tion template was derived from the entire imaging dataset
(HC, pro-DLB and pro-AD). Third, after an initial affine
transformation of the GM DARTEL template to the GM
tissue probability map in Montreal Neurological Institute
(MNI) space (http://www.mni.mcgill.ca/), non-linear
warping of the segmented images was performed, match-
ing the MNI space GM DARTEL template. Fourth, images
were modulated to ensure that relative volumes of GM
were preserved following spatial normalisation. Last,
images were smoothed with an 8-mm full-width at half-
maximum 3D Gaussian kernel. The spatially pre-
processed scans were then used for voxel-wise statistical
analysis.
Statistical analysis
Controlling for age, total intracranial volume (TIV) and
sex, group differences were assessed using the general-
ised linear model in SPM8, and statistical significance
was estimated with the distributional approximations of
Gaussian random fields [36]. Multiple regression ana-
lyses were also performed to investigate effects of GM
loss on selected cognitive variables in pro-DLB (adjusted
for age and TIV). Significant effects were identified using
the corrected family-wise error (FWE) P value threshold
(PFWE ≤ 0.05). IBM SPSS version 22.0.0.0 software (IBM,
Armonk, NY, USA) was used for further statistical evalu-
ation as required. Where appropriate, differences in
demographic and clinical data were assessed using para-
metric (analysis of variance [ANOVA], t test) and non-
parametric (Kruskal-Wallis H test, Mann-Whitney U
test) tests. In post hoc analyses, we employed Tukey’s
test and the Mann-Whitney U test for ANOVA and
Kruskal-Wallis tests, respectively. For categorical mea-
sures, χ2 tests were applied. For each test statistic, a
probability value <0.05 was regarded as significant.
Results
Subject characteristics
The demographic data for patients and HC are sum-
marised in Table 1. Subject groups were well matched
for education, sex and handedness. Of the patients with
pro-AD, 9 presented with an amnestic MCI single do-
main and 18 with amnestic MCI multiple domains. Of
the patients with pro-DLB, 2 presented with amnestic
MCI multiple domains, 13 with a non-amnestic MCI
single domain and 13 with non-amnestic MCI multiple
domains. For pro-AD and pro-DLB, MMSE and CDR
scores were similar. For TMTA and TMTB, patients
with pro-DLB were more impaired than the HC group.
Patients with pro-DLB were more likely to have halluci-
nations and had higher motor parkinsonism (UPDRS III
scores) and CAF scores. They also had a higher preva-
lence of rapid eye movement sleep behaviour disorder
(RBD) than the prevalence in the other groups. Patients
with pro-DLB were on dopaminergic treatment and had
the highest use of neuroleptics (clozapine and quetia-
pine) compared with other groups. Patients with pro-AD
had a greater number of abnormal CSF biomarkers than
patients with pro-DLB. Among 23 patients with pro-
DLB, only one had an abnormal level Aβ1–42. Upon vis-
ual rating of hippocampal atrophy on MRI scans, we
found that patients with pro-AD had more atrophy than
HC. Patients with pro-DLB had more atrophy than HC
only for the left hippocampus. Patients with pro-AD had
more hippocampal atrophy than patients with pro-DLB
only for the right hippocampus.
Voxel-based morphometry group effects
VBM analysis revealed, relative to HC, significant GM
volume loss in pro-DLB bilaterally in the insula, precu-
neus and medial frontal structures, as well as in the left
anterior cingulate, left middle frontal, right superior and
inferior frontal regions (Fig. 2a). Table 2 depicts the loca-
tion and peak significance of these areas. No GM vol-
ume losses were apparent in HC that were greater than
those in pro-DLB.
A more extensive atrophic pattern was apparent in
pro-AD compared with HC, showing significant bilateral
GM loss in the hippocampal, frontal (inferior, medial,
superior gyri) and middle temporal gyrus, as well as in
the posterior and mid-cingulate regions (Fig. 2b). Other
unilateral areas included the cerebellum, precuneus, in-
ferior occipital, and middle frontal and superior parietal
regions. Table 2 shows the location and peak significance
of the regions. No GM deficits were observed in HC
which exceeded those in pro-AD.
Between patient groups, differences in GM atrophy
were much decreased and confined to the right su-
perior parietal region in pro-AD relative to pro-DLB
(Fig. 2c). Table 2 presents the location and peak
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Table 1 Clinical and demographic features of patients with dementia with Lewy bodies patients, Alzheimer’s disease at the mild cognitive impairment or prodromal stage, and
healthy elderly control subjects
Pro-DLB (n = 28; 2 NCL, 26 SXB) Pro-AD (n = 27; 1 NCL, 26 SXB) HC (n = 33; 30 NCL, 3 SXB) Test statistic, P value Post hoc analysisa
Age, years, mean (SD) 67.5 (9.2) 69.3 (7.8) 72.4 (10.4) F = 2.189, P = 0.118
Education,b 1/2/3 11/4/8 11/3/12 1/14/11 H = 2.116, P = 0.347
Sex, F/M 16/12 7/20 18/15 χ2 = 6.726, P = 0.035c
Handedness, R/L 26/2 24/3 29/4 χ2 = 1.558, P = 0.459
MMSE score 27.6 (2.1) 26.9 (1.9) 29.4 (0.9) H = 31.897, P < 0.0001c HC > pro-AD and pro-DLB
TMTA,d impaired subjects 60.7 % 32.0 % 0 % H = 12.174, P < 0.002c HC > pro-DLB
TMTB,d impaired subjects 71.4 % 44.0 % 0 % H = 15.245, P < 0.0001c HC > pro-DLB
CDR Sum of Boxes, 0/0.5/1/2/3 2/26/0/0/0 1/26/0/0/0 33/0/0/0/0 H = 75.466, P < 0.0001c HC < pro-DLB and pro-AD
Parkinsonisme
Rigidity, 0/1/2/3/4 7/20/1/0/0 23/4/0/0/0 33/0/0/0/0 H = 44.388, P < 0.0001c Pro-DLB > HC and pro-AD
Akinesia, 0/1/2/3/4 10/14/3/1/0 23/4/0/0/0 31/2/0/0/0 H = 29.156, P < 0.0001c Pro-DLB > HC and pro-AD
Tremor at rest, 0/1/2/3/4 17/9/2/0/0 27/0/0/0/0 33/0/0/0/0 H = 19.360, P < 0.0001c Pro-DLB > HC and pro-AD
Hallucinations 60.7 % 0 % 0 % χ2 = 44.521, P < 0.0001c
Fluctuations 92.9 % 0 % 0 % χ2 = 65.972, P < 0.0001c
CAFb 3.5 (3.6) 0.0 (0) 0 (0) H = 34.872, P < 0.0001c Pro-DLB > HC and pro-AD
RBD 56.0 % 7.7 % 0 % H = 31.696, P < 0.0001c Pro-DLB > HC and pro-AD
Treatment
ChEI 28.6 % 48.1 % 0.0 % χ2 = 18.253, P < 0.0001c
Dopa 28.6 % 0.0 % 0.0 % χ2 = 19.274, P < 0.0001c
NL 10.7 % 0.0 % 0.0 % χ2 = 6.793, P = 0.033c
CSF, mean (SD), number of subjects
Aβ1–42 859.3 (336.7) n = 23 579.0 (287.4), n = 23 – F = 5.345, P = 0.008c Pro-DLB > pro-AD
Phospho-tau 43.6 (13.9), n = 23 93.7 (36.8), n = 23 – F = 18.805, P < 0.0001c Pro-DLB < pro-AD
Tau 313.0 (286.3), n = 23 660.6 (355.4), n = 23 – F = 6.895, P = 0.002c Pro-DLB < pro-AD
Hippocampal atrophy,f 0/1/2/3/4
Left hippocampus 14/10/2/2/0 5/16/4/2/0 27/5/1/0/0 H = 23.992, P < 0.0001c HC < pro-AD and pro-DLB
Right Hippocampus 14/10/4/0/0 5/14/7/1/0 22/8/2/1/0 H = 13.591, P < 0.001c Pro-AD < HC and pro-DLB
Abbreviations: Aβ1–42 amyloid-β1–42, CAF Clinician Assessment of Fluctuation, CDR Clinical Dementia Rating, ChEI cholinesterase inhibitor, CSF cerebrospinal fluid, Dopa levodopa or dopaminergic agonists, HC healthy
elderly control subjects, MMSE Mini Mental State Examination, NCL old age psychiatry, geriatric medicine or neurology services from Newcastle upon Tyne, NL neuroleptic, pro-AD prodromal Alzheimer’s disease,
pro-DLB prodromal dementia with Lewy bodies, RBD rapid eye movement sleep behaviour disorder, SXB tertiary memory clinic of Strasbourg, TMT Trail Making Test
aTukey’s post hoc test for analysis of variance (F), Mann-Whitney post hoc test in IBM SPSS software (H)
bEducation level: 1 = before high school, 2 = high school, 3 = university
cStatistically significant value
dpercentage of patients with test failure according to the normative data of Tombaugh, 2004 [30]
eAs rated on Unified Parkinson’s Disease Rating Scale [28]
fAccording to Scheltens et al. [31]
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significance of this area. No significant GM loss
was found in pro-DLB that was greater than that in
pro-AD.
As an exploratory exercise, we also investigated pat-
terns of GM loss between visual hallucinators and non-
hallucinators in pro-DLB. Significant GM volume loss in
the left cuneus was associated with the presence of vis-
ual hallucinations (Fig. 3). Table 2 presents the location
and peak significance of these areas. GM atrophy in
non-hallucinators did not exceed that in hallucinators.
Regression analyses
Effects of GM volume loss on parkinsonism and fluctua-
tions were separately investigated in pro-DLB (age, sex
and TIV adjusted). Associations between any of these
measures and GM volume did not yield any significant
results.
Discussion
We report distinct GM atrophy in pro-DLB and pro-AD
compared with HC. Compared with HC the group, the
pro-DLB group was characterised by cortical atrophy in
insulae, structures and anterior cingulate cortex. Com-
pared with HC, pro-AD was characterised by a wide-
spread cortical atrophic pattern which included the
hippocampi and temporal, parietal and frontal struc-
tures. The comparison of patients with pro-AD with pa-
tients with pro-DLB demonstrated more atrophy the
right parietal lobe in the former than in the latter group.
The results we obtained with patients with pro-AD are
in accord with the literature. The progression of atrophy
with time in pro-AD was previously described as begin-
ning in the medial temporal lobes [37], then extending
to the parietal and finally the frontal lobes [27, 38, 39].
On one hand, the strong involvement of the frontal
lobe is unusual in MCI-AD [38]. On the other hand,
more impaired MCI [40] and MCI converters to AD
dementia [41] have greater atrophy in the frontal lobe
at the initial scan.
The atrophy found in patients with pro-DLB com-
pared with HC has not been described previously, to our
knowledge. Notably, we obtained similar results with the
same patients on the basis VBM-DARTEL as we did
with FreeSurfer methods [13], showing clear atrophic in-
volvement of the anterior insulae in pro-DLB. Previ-
ously, we observed that cortical thinning was more
apparent in the right insula, whereas in the present
study, we observed GM insular atrophy bilaterally. This
may reflect subtleties between MRI techniques when
quantifying volumetric changes [42]. However, the dis-
covery of the insula change in pro-DLB with two tech-
niques in the same cohort reinforces the link between
pro-DLB and early changes in the insula. This overlaps
with voxel-wise meta-analytic data on cortical atrophy of
patients with DLB at the stage of dementia, based on
findings of bilateral insular and basal ganglia atrophy
[22]. The insula is involved in integrating somatosensory,
Fig. 2 Significant grey matter (GM) loss in the prodromal dementia
with Lewy bodies (pro-DLB) (a) and prodromal Alzheimer’s disease
(pro-AD) (b) groups relative to healthy older control subjects. GM
atrophy in pro-AD compared with pro-DLB (c). Results (PFWE ≤ 0.05)
are superimposed upon a magnetic resonance imaging T1-weighted
brain template image in axial views. L left, R right, FWE family-wise error
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autonomic and cognitive-affective information to guide
behaviour [43], and specifically the anterior insula has
been described as part of a ‘salience network’ due to its
consistent activation during cognitively demanding tasks.
It also has been implicated in switching brain networks
involved in cognition, including the central executive
and default mode network [44]. The anterior insula has
an abundance of specific neurons, namely the von Econ-
omo neurons (VENs), located in layer 5 of the cortex
with a predominance in the right hemisphere, the same
Table 2 Location and peak significance of grey matter volume loss using VBM-DARTEL
Voxel level (PFWE) Extent (k) T, Z scores MNI coordinates (x, y, z) (mm) Region
Pro-DLB vs. control subjects <0.001 2361 7.1, 6.0 11, 57, 18 Right superior frontal
7.1, 6.0 9, 50, 13 Right paracingulate
<0.001 461 6.8, 5.8 −38, 11, 13 Left insula
0.001 1321 6.4, 5.5 −29, 24, −6 Left insula
0.001 340 6.1, 5.3 −8, −63, 45 Left precuneus
0.002 53 5.9, 5.2 14, −43, 43 Right precuneus
0.002 359 5.9, 5.2 30, 29, −3 Right inferior frontal
0.006 137 5.6, 5.0 39, 5, 7 Right insula
0.009 35 5.5, 4.9 5, 68, −3 Right medial frontal
0.016 25 5.3, 4.8 −14, 60, 7 Left medial frontal
0.017 15 5.3, 4.8 −29, 29, 40 Left middle frontal
0.018 31 5.3, 4.7 26, 56, −11 Right superior frontal
0.033 12 5.1, 4.6 −14, 47, 0 Left anterior cingulate
Pro-AD vs. control subjects <0.001 24,640 9.8, 7.4 12, 59, −15 Right medial frontal
8.6, 6.8 50, 47, −3 Right inferior frontal
8.0, 6.5 −30, −19, −18 Left hippocampus
7.4, 6.2 42, 54, −14 Right middle frontal
7.3, 6.1 −44, 26, −5 Left inferior frontal
7.3, 6.1 −12, 62, −3 Left medial frontal
7.3, 6.1 −9, 69, −-9 Left superior frontal
<0.001 1144 6.7, 5.7 35, 21, −42 Right temporal pole
6.1, 5.3 39, 8, −33 Right superior temporal
0.001 1881 6.3, 5.5 12, −39, 42 Right posterior cingulate
6.1, 5.3 −8, −39, 40 Left posterior cingulate
0.002 176 6.0, 5.2 33, −81, −53 Right posterior cerebellum
0.003 67 5.9, 5.2 11, −9, 39 Right mid-cingulate
0.004 392 5.8, 5.1 15, 24, 61 Right superior frontal
0.004 94 5.8, 5.1 −47, −84, −9 Left inferior occipital
0.004 145 5.8, 5.1 −5, −48, −27 Left anterior cerebellum
0.005 527 5.7, 5.0 −33, −70, 39 Left precuneus
0.007 178 5.6, 5.0 −11, 15, 39 Left mid-cingulate
0.008 113 5.5, 4.9 48, −76, 24 Right middle temporal
0.011 12 5.4, 4.8 18, −72, 56 Right superior parietal
0.011 137 5.4, 4.8 29, −12, −14 Right hippocampus
0.012 42 5.4, 4.8 −60, 2, −27 Left middle temporal
Pro-AD vs. pro-DLB 0.006 79 5.6, 4.9 20, −42, 60 Right superior parietal
Pro-DLB (hallucinators vs. non-hallucinators) 0.002a 82 3.1, 2.8 −5, −84, 18 Left cuneus BA17
Abbreviations: BA Brodmann area, FWE family-wise error, MNI Montreal Neurological Institute, pro-AD prodromal Alzheimer’s disease, pro-DLB prodromal dementia
with Lewy bodies, VBM-DARTEL voxel-based morphometry with diffeomorphic anatomical registration through exponentiated lie algebra
Table depicts voxel-level significance (PFWE), spatial extent (k), T and Z scores, MNI coordinates and anatomical region
aUncorrected P value
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region we have found to be atrophic and thinner in pro-
DLB [45]. Notably, in the right anterior cingulate cortex,
an area which we found to be atrophic in this study, is
also rich in VENs. Because of the larger size of VENs
compared with pyramid neurons, they are purported be
involved in the fast assessment of complex situations
[45], as well as in the salience network function [46],
and thus it might be hypothesised that deficits in this re-
gion might be pertinent to the cognitive slowing and at-
tentional deficits which characterise DLB. This is
supported by the observation that increasing functional
dyssynchrony between frontal areas inclusive of the in-
sula and parietal areas, as measured using resting state
MRI, is associated with increasing cognitive fluctuations
in patients with DLB [24]. Whether there is a specific
vulnerability of VENs in DLB remains to be confirmed,
however.
When we compared pro-DLB with pro-AD, we found
subtle right parietal GM volume reductions in patients
with pro-AD, and this is in line with our previous find-
ings demonstrating cortical thinning of this region in
AD compared with DLB [13]. Notably, we did not find
evidence of any relative atrophy of the hippocampi in
pro-AD compared with pro-DLB. However, this is con-
sistent with our visual rating data which demonstrated
that both groups had relatively mild hippocampal atro-
phy at the prodromal stage, with only subtle differences
between the two diseases. Longitudinally, however, it
might be expected that there would be an increasing di-
vergence between pro-AD and pro-DLB cohorts, with
greater hippocampal loss in the former; certainly, longi-
tudinal comparisons in established dementia demon-
strate that marked temporal and hippocampal thinning
is a feature of AD but not DLB [47].
We found an association between GM loss in the left
cuneus and visual hallucinations in our pro-DLB group.
The cuneus is a secondary visual area (Brodmann area
18) and is of importance for recognition and extraction
of object features (shape, colour, movement). Dysfunc-
tion of the cuneus is responsible for errors in visual pro-
cessing [48]. The involvement of this visual area in
hallucinations of patients with DLB is consistent with
previous studies [48–50]. The involvement of the cuneus
is congruent with the top-down/bottom-up models on
hallucinations [51], since we have found a key region for
visual processing (bottom-up).
Our study has some limitations. In the present study,
we have used a combination of pre-existing criteria for
MCI and DLB, but a primary issue is that operational
consensus criteria for pro-DLB remain to be established.
In addition, whilst patients continue to be followed lon-
gitudinally, our cohort is relatively recent in its incep-
tion, and the definite diagnostic trajectory of patients
with prodromal impairment remains to be established
either clinically or neuropathologically, particularly with
regard to DLB. Moreover, the possibility that an incor-
rect classification of patients confounded the results
cannot be excluded. However, we used the McKeith
et al. criteria, which have an excellent specificity
(>95 %) [52, 53] compared with gold standard
Fig. 3 Significant grey matter loss in prodromal dementia with Lewy bodies (pro-DLB) visual hallucinators compared with pro-DLB non-hallucinators.
Results (Puncorrected≤ 0.005) superimposed on a magnetic resonance imaging T1-weighted brain template scan in axial (on the left) and sagittal (on the
right, b). L left, R right
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neuropathological diagnosis. In addition, we excluded
other pathologies, such as psychiatric illness, other
neurological diseases and co-occurrence of AD and
DLB (see Fig. 1 flowchart). Furthermore, the major-
ity of our patients with pro-DLB had RBD (>50 %),
which enhances the specificity of the diagnosis [54].
We also systematically looked for subtle clinical
symptoms such as anosmia/hyposmia, constipation
and other autonomic features (data not shown) [55],
as these have previously been demonstrated to im-
prove the diagnostic specificity of patients with pro-
DLB [55]. Finally, we used CSF analysis for most of
the patients and obtained similar results for patients
with AD and patients with DLB.
From a technical perspective, it could also be argued
that a drawback of our study is the fact that data were
collected from two sites with differing imaging protocols.
Unfortunately, we were not able to include MRI se-
quences in the model, as the relative numbers in each
group were disproportionately represented (i.e., 30 HC
at NCL, 3 at SXB; 1 AD at NCL, 26 at SXB; and 2 DLB
at NCL, 26 at SXB). Therefore, it was difficult to obtain
accurate parametric estimates without considerable
error. However, centre effects were less likely to have in-
fluenced the between-patient contrast, as the results did
not significantly differ when we examined only SXB pa-
tients in the analysis. A single-centre study should be
conducted to confirm these results. Last, in a possible
future analysis using resampling/subsampling tech-
niques, the reliability of the prodromal results could be
examined for validation purposes, although this would
require larger cohorts.
Conclusions
Our data suggest that patients with prodromal disease
have different patterns of atrophy depending on the
pathology. Patients with pro-DLB seem to have more re-
stricted areas of atrophy inclusive of the insulae and an-
terior cingulate cortex, and patients with pro-AD have
more diffuse areas. New studies using MRI are acutely
needed, particularly those considering perfusion, func-
tional connectivity and structural connectivity, as well as
other imaging modalities, such as positron emission
tomography metabolic and amyloid radiotracers, to bet-
ter understand the specificity of patients with pro-DLB.
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